Professional
Added to YB: 2025-11-03
Pitch date: 2025-09-30
MDGL [neutral]
Madrigal Pharmaceuticals, Inc.
+24.39%
current return
Author Info
No bio for this author
Company Info
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
Market Cap
$12.0B
Pitch Price
$450.65
Price Target
N/A
Dividend
N/A
EV/EBITDA
-36.87
P/E
-40.60
EV/Sales
15.20
Sector
Biotechnology
Category
growth
Meridian Growth Fund Portfolio Holding: Madrigal Pharmaceuticals, Inc.
MDGL trimmed position: Commercial-stage biopharma w/ Rezdiffra for MASH liver disease showing very strong launch execution, on pace for >$1B annualized sales. Single-digit US penetration suggests multi-billion blockbuster potential. Pipeline includes in-licensed oral GLP-1. Trimmed on appreciation.
Read full article (1 min)